Clinical Trial

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 28, 2025 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Efficacy and Safety of Selinexor Combined with Azacitidine as Maintenance Therapy in High-Risk Myeloid Neoplasms Patients Post-Transplantation: A Single-Center, Single-Arm, Exploratory Study
Trial Details
NCT Number NCT06900088
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Enrollment 20 participants
Start Date 2025-04-25
Primary Completion 2025-10-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-28